Table 5.
Gene | dbSNP [6] rel. 147 or see [Ref] | 5′ flank |
wt
mut |
3′ flank | KD, nM | Known diseases (SNP markers) or hypothetical disease (candidate SNP markers) | [Ref] or [this work] | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
wt
mut |
Δ | Z | α | ρ | |||||||
HBB | rs397509430 | gggctgggca |
t
- |
atacaacagt |
5
29 |
↓ | 34 | 10-6 | A | malaria resistance and thalassemia | [176] |
rs33980857 | gggctgggca |
t
a,g,c |
atacaacagt |
5
21 |
↓ | 27 | 10-6 | A | |||
rs34598529 | ggctgggcat |
a
g |
aaagtcaggg |
5
18 |
↓ | 24 | 10-6 | A | |||
rs33931746 | gctgggcata |
a
g,c |
aagtcagggc |
5
11 |
↓ | 14 | 10-6 | A | |||
rs33981098 | agggctgggc |
a
g,c |
taaaagtcag |
5
9 |
↓ | 10 | 10-6 | A | |||
rs34500389 | cagggctggg |
c
a,t,g |
ataaaagtca |
5
6 |
↓ | 3 | 10-2 | C | |||
(hypothetically) the same disease; heterozygotes “wt-mut” are still more viable according to most of clinical indicators in comparison with both homozygotes “wt-wt” and “mut-mut” | [this work], [185] | ||||||||||
rs63750953 | ctgggcataa |
aa
- |
gtcagggcag |
5
8 |
↓ | 9 | 10 -6 | A | |||
rs281864525 | tgggcataaa |
a
c |
gtcagggcag |
5
7 |
↓ | 7 | 10 -6 | A | |||
rs117785782 | ggctgagggt |
t
c |
tgaagtccaa |
28
39 |
↓ | 7 | 10 -6 | A | |||
HBD | rs35518301 | caggaccagc |
a
g |
taaaaggcag |
4
8 |
↓ | 11 | 10-6 | A | malaria resistance and thalassemia | [176] |
(hypothetically) the same disease; heterozygotes “wt-mut” are still more viable according to most of clinical indicators | [this work], [185] | ||||||||||
rs34166473 | aggaccagca |
t
c |
aaaaggcagg |
4
8 |
↓ | 18 | 10 -6 | A | |||
HBG2 | rs745580140 | ggagttgctc |
ta
- |
cacaagctct |
11
22 |
↓ | 10 | 10 -6 | A | ||
ACKR1 | rs2814778 | ttggctctta |
t
c |
cttggaagca |
10
12 |
↓ | 4 | 10-3 | B | low white-blood-cell count and resistance to malaria, (hypothetically) pre-eclampsia | [177, 178], [this work], [186] |
MBL2 | rs72661131 | tctatttcta |
t
c |
atagcctgca |
2
4 |
↓ | 12 | 10-6 | A | variable immunedefici-ency, pre-eclampsia, stroke, | [190–192] |
(hypothetically) the same disease; higher risks of recurrent vulvovaginal infections | [this work], [187] | ||||||||||
rs562962093 | atctatttct |
a
g |
tatagcctgc |
2
5 |
↓ | 15 | 10-6 | A | |||
rs567653539 | tttctatata |
g
a |
cctgcaccca |
2
1 |
↑ | 12 | 10-6 | A | (hypothetically) reduced risks of recurrent vulvovaginal infections | ||
MMP12 | rs2276109 | gatatcaact |
a
g |
tgagtcactc |
11
14 |
↓ | 3 | 10-2 | C | lower risk of psoriasis, systemic sclerosis, asthma | [193–195] |
(hypothetically), higher risk of ovarian hyper-stimulation syndrome | [this work], [188] | ||||||||||
rs572527200 | gatgatatca |
a
g |
ctatgagtca |
11
14 |
↓ | 3 | 10-2 | C | |||
F2 | rs564528021 | agttcaacat |
t
c |
aacccagagg |
13
9 |
↑ | 7 | 10-6 | A | (hypothetically) high risk of pre-eclampsia | [this work], [189] |
rs752364393 | caacattaac |
c
t |
cagaggggtc |
13
11 |
↑ | 3 | 10-3 | B |
See “Note” under Table 1